File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors

TitleHER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors
Authors
Issue Date2009
Citation
Clinical Cancer Research, 2009, v. 15 n. 15, p. 4829-4837 How to Cite?
AbstractPurpose: To compare the characteristics of deregulation of HERre ceptors and their ligands between primary tumor and corresponding brain metastases of non - small cell lung carcinoma (NSCLC). Experimental Design: Fifty-five NSCLC primary tumors and corresponding brain metastases specimens were examined for the immunohistochemical expression of epidermal growth factor receptor (EGFR), phosphorylated EGFR, Her2, Her3, and phosphorylated Her3, and their ligands EGF, transforming growth factor-a, amphiregulin, epiregulin, betacellulin, heparin-binding EGFR-like growth factor, neuregulin (NRG) 1, and NRG2. Analysis of EGFR copy number using fluorescence in situ hybridization and mutation by PCR-based sequencing was also done. Results: Metastases showed significantly higher immunohistochemical expression of EGF (membrane: brain metastases 66.0 versus primary tumors 48.5; P = 0.027; nucleus: brain metastases 92.2 versus 67.4; P = 0.008), amphiregulin (nucleus: brain metastases 53.7 versus primary tumors 33.7; P = 0.019), phosphorylated EGFR( membrane: brain metastases 161.5 versus primary tumors 76.0; P < 0.0001; cytoplasm: brainmetastases101.5 versus primary tumors 55.9; P = 0.014), and phosphorylated Her3 (membrane: brain metastases 25.0 versus primary tumors 3.7; P = 0.001) than primary tumors did. Primary tumors showed significantly higher expression of cytoplasmic transforming growth factor-α(primary tumors 149.8 versus brain metastases 111.3; P = 0.008) and NRG1 (primary tumors 158.5 versus brain metastases 122.8; P = 0.006). In adenocarcinomas, a similar high frequency of EGFR copy number gain (high polysomy and amplification) was detected in primary (65%) and brain metastasis (63%) sites. However, adenocarcinoma metastases (30%) showed higher frequency of EGFR amplification than corresponding primary tumors (10%). Patients whose primary tumors showed EGFR amplification tended to develop brainmetastases at an earlier time point. Conclusions: Our findings suggest that NSCLC brain metastases have some significant differences in HERf amily receptor - related abnormalities from primary lung tumors. © 2009 American Association for Cancer Research.
Persistent Identifierhttp://hdl.handle.net/10722/146593
ISSN
2015 Impact Factor: 8.738
2015 SCImago Journal Rankings: 5.314
ISI Accession Number ID
Funding AgencyGrant Number
Department of DefenseW81XWH-05-0027
Funding Information:

Grant support: Department of Defense grant W81XWH-05-0027.

References

 

DC FieldValueLanguage
dc.contributor.authorSun, Men_HK
dc.contributor.authorBehrens, Cen_HK
dc.contributor.authorFeng, Len_HK
dc.contributor.authorOzburn, Nen_HK
dc.contributor.authorTang, Xen_HK
dc.contributor.authorYin, Gen_HK
dc.contributor.authorKomaki, Ren_HK
dc.contributor.authorVarellaGarcia, Men_HK
dc.contributor.authorWaun, KHen_HK
dc.contributor.authorAldape, KDen_HK
dc.contributor.authorWistuba, IIen_HK
dc.date.accessioned2012-05-02T08:37:16Z-
dc.date.available2012-05-02T08:37:16Z-
dc.date.issued2009en_HK
dc.identifier.citationClinical Cancer Research, 2009, v. 15 n. 15, p. 4829-4837en_HK
dc.identifier.issn1078-0432en_HK
dc.identifier.urihttp://hdl.handle.net/10722/146593-
dc.description.abstractPurpose: To compare the characteristics of deregulation of HERre ceptors and their ligands between primary tumor and corresponding brain metastases of non - small cell lung carcinoma (NSCLC). Experimental Design: Fifty-five NSCLC primary tumors and corresponding brain metastases specimens were examined for the immunohistochemical expression of epidermal growth factor receptor (EGFR), phosphorylated EGFR, Her2, Her3, and phosphorylated Her3, and their ligands EGF, transforming growth factor-a, amphiregulin, epiregulin, betacellulin, heparin-binding EGFR-like growth factor, neuregulin (NRG) 1, and NRG2. Analysis of EGFR copy number using fluorescence in situ hybridization and mutation by PCR-based sequencing was also done. Results: Metastases showed significantly higher immunohistochemical expression of EGF (membrane: brain metastases 66.0 versus primary tumors 48.5; P = 0.027; nucleus: brain metastases 92.2 versus 67.4; P = 0.008), amphiregulin (nucleus: brain metastases 53.7 versus primary tumors 33.7; P = 0.019), phosphorylated EGFR( membrane: brain metastases 161.5 versus primary tumors 76.0; P < 0.0001; cytoplasm: brainmetastases101.5 versus primary tumors 55.9; P = 0.014), and phosphorylated Her3 (membrane: brain metastases 25.0 versus primary tumors 3.7; P = 0.001) than primary tumors did. Primary tumors showed significantly higher expression of cytoplasmic transforming growth factor-α(primary tumors 149.8 versus brain metastases 111.3; P = 0.008) and NRG1 (primary tumors 158.5 versus brain metastases 122.8; P = 0.006). In adenocarcinomas, a similar high frequency of EGFR copy number gain (high polysomy and amplification) was detected in primary (65%) and brain metastasis (63%) sites. However, adenocarcinoma metastases (30%) showed higher frequency of EGFR amplification than corresponding primary tumors (10%). Patients whose primary tumors showed EGFR amplification tended to develop brainmetastases at an earlier time point. Conclusions: Our findings suggest that NSCLC brain metastases have some significant differences in HERf amily receptor - related abnormalities from primary lung tumors. © 2009 American Association for Cancer Research.en_HK
dc.languageengen_US
dc.relation.ispartofClinical Cancer Researchen_HK
dc.subject.meshBrain Neoplasms - Metabolism - Pathology - Secondaryen_US
dc.subject.meshCarcinoma, Non-Small-Cell Lung - Metabolism - Pathology - Secondaryen_US
dc.subject.meshFemaleen_US
dc.subject.meshGene Dosage - Genetics - Physiologyen_US
dc.subject.meshHumansen_US
dc.subject.meshLigandsen_US
dc.subject.meshLung Neoplasms - Metabolism - Pathology - Secondaryen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPoint Mutation - Geneticsen_US
dc.subject.meshReceptor, Epidermal Growth Factor - Metabolismen_US
dc.subject.meshReceptor, Erbb-2 - Metabolismen_US
dc.subject.meshReceptor, Erbb-3 - Metabolismen_US
dc.titleHER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumorsen_HK
dc.typeArticleen_HK
dc.identifier.emailYin, G: gyin@hku.hken_HK
dc.identifier.authorityYin, G=rp00831en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1158/1078-0432.CCR-08-2921en_HK
dc.identifier.pmid19622585-
dc.identifier.scopuseid_2-s2.0-68049147562en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-68049147562&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume15en_HK
dc.identifier.issue15en_HK
dc.identifier.spage4829en_HK
dc.identifier.epage4837en_HK
dc.identifier.isiWOS:000268861600008-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridSun, M=14833715200en_HK
dc.identifier.scopusauthoridBehrens, C=7005441177en_HK
dc.identifier.scopusauthoridFeng, L=34770041700en_HK
dc.identifier.scopusauthoridOzburn, N=15119554800en_HK
dc.identifier.scopusauthoridTang, X=7404100928en_HK
dc.identifier.scopusauthoridYin, G=8725807500en_HK
dc.identifier.scopusauthoridKomaki, R=35375100800en_HK
dc.identifier.scopusauthoridVarellaGarcia, M=7003396171en_HK
dc.identifier.scopusauthoridWaun, KH=34574269600en_HK
dc.identifier.scopusauthoridAldape, KD=7003279836en_HK
dc.identifier.scopusauthoridWistuba, II=35375776900en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats